165 related articles for article (PubMed ID: 17929018)
1. Economic evaluation of caspofungin vs liposomal amphotericin B for empirical therapy of suspected systemic fungal infection in the German hospital setting.
Kaskel P; Tuschy S; Wagner A; Bannert C; Cornely OA; Glasmacher A; Lipp HP; Ullmann AJ
Ann Hematol; 2008 Apr; 87(4):311-9. PubMed ID: 17929018
[TBL] [Abstract][Full Text] [Related]
2. Pharmacoeconomic evaluation of caspofungin versus liposomal amphotericin B in empirical treatment of invasive fungal infections in Turkey.
Turner SJ; Senol E; Kara A; Al-Badriyeh D; Kong DC; Dinleyici EC
Int J Antimicrob Agents; 2013 Sep; 42(3):276-80. PubMed ID: 23830892
[TBL] [Abstract][Full Text] [Related]
3. Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia.
Walsh TJ; Teppler H; Donowitz GR; Maertens JA; Baden LR; Dmoszynska A; Cornely OA; Bourque MR; Lupinacci RJ; Sable CA; dePauw BE
N Engl J Med; 2004 Sep; 351(14):1391-402. PubMed ID: 15459300
[TBL] [Abstract][Full Text] [Related]
4. A cost-effectiveness analysis of caspofungin vs. liposomal amphotericin B for treatment of suspected fungal infections in the UK.
Bruynesteyn K; Gant V; McKenzie C; Pagliuca T; Poynton C; Kumar RN; Jansen JP
Eur J Haematol; 2007 Jun; 78(6):532-9. PubMed ID: 17419744
[TBL] [Abstract][Full Text] [Related]
5. Economic evaluation of caspofungin versus liposomal amphotericin B for empiric antifungal treatment in patients with neutropenic fever in Italy.
Stam WB; Aversa F; Kumar RN; Jansen JP
Value Health; 2008; 11(5):830-41. PubMed ID: 18494752
[TBL] [Abstract][Full Text] [Related]
6. Economic evaluation of caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia in Sweden.
Naik S; Lundberg J; Kumar R; Sjolin J; Jansen JP
Scand J Infect Dis; 2011 Jul; 43(6-7):504-14. PubMed ID: 21332286
[TBL] [Abstract][Full Text] [Related]
7. A randomized, double-blind, multicenter study of caspofungin versus liposomal amphotericin B for empiric antifungal therapy in pediatric patients with persistent fever and neutropenia.
Maertens JA; Madero L; Reilly AF; Lehrnbecher T; Groll AH; Jafri HS; Green M; Nania JJ; Bourque MR; Wise BA; Strohmaier KM; Taylor AF; Kartsonis NA; Chow JW; Arndt CA; DePauw BE; Walsh TJ;
Pediatr Infect Dis J; 2010 May; 29(5):415-20. PubMed ID: 20431381
[TBL] [Abstract][Full Text] [Related]
8. Economic impact of caspofungin as compared with liposomal amphotericin B for empirical therapy in febrile neutropenia in Australia.
Al-Badriyeh D; Liew D; Stewart K; Kong DC
J Antimicrob Chemother; 2009 Jun; 63(6):1276-85. PubMed ID: 19346292
[TBL] [Abstract][Full Text] [Related]
9. Pharmacoeconomic analysis of caspofungin versus liposomal amphotericin B as empirical antifungal therapy for neutropenic fever.
Wingard JR; Leather HL; Wood CA; Gerth WC; Lupinacci RJ; Berger ML; Mansley EC
Am J Health Syst Pharm; 2007 Mar; 64(6):637-43. PubMed ID: 17353573
[TBL] [Abstract][Full Text] [Related]
10. Cost-effectiveness of caspofungin versus liposomal amphotericin B in the treatment of systemic fungal infections: a systematic review of economic analyses.
Mistro S; Rosa L; Gomes B; Miranda L; Badaró R
Expert Rev Pharmacoecon Outcomes Res; 2016 Aug; 16(4):465-73. PubMed ID: 27322156
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and Safety of Echinocandins for the Treatment of Invasive Candidiasis in Children: A Meta-analysis.
Tsekoura M; Ioannidou M; Pana ZD; Haidich AB; Antachopoulos C; Iosifidis E; Kolios G; Roilides E
Pediatr Infect Dis J; 2019 Jan; 38(1):42-49. PubMed ID: 29596219
[TBL] [Abstract][Full Text] [Related]
12. Caspofungin as antifungal prophylaxis in pediatric patients undergoing allogeneic hematopoietic stem cell transplantation: a retrospective analysis.
Döring M; Hartmann U; Erbacher A; Lang P; Handgretinger R; Müller I
BMC Infect Dis; 2012 Jul; 12():151. PubMed ID: 22747637
[TBL] [Abstract][Full Text] [Related]
13. Caspofungin versus liposomal amphotericin B for treatment of invasive fungal infections or febrile neutropenia.
Zhang J; Gong Y; Wang K; Kong J; Chen Y
Chin Med J (Engl); 2014; 127(4):753-7. PubMed ID: 24534235
[TBL] [Abstract][Full Text] [Related]
14. Economic Comparison of an Empirical Versus Diagnostic-Driven Strategy for Treating Invasive Fungal Disease in Immunocompromised Patients.
Barnes R; Earnshaw S; Herbrecht R; Morrissey O; Slavin M; Bow E; McDade C; Charbonneau C; Weinstein D; Kantecki M; Schlamm H; Maertens J
Clin Ther; 2015 Jun; 37(6):1317-1328.e2. PubMed ID: 25891805
[TBL] [Abstract][Full Text] [Related]
15. Economic analysis of micafungin versus liposomal amphotericin B for treatment of candidaemia and invasive candidiasis in Germany.
Cornely OA; Sidhu M; Odeyemi I; van Engen AK; van der Waal JM; Schoeman O
Curr Med Res Opin; 2008 Jun; 24(6):1743-53. PubMed ID: 18477422
[TBL] [Abstract][Full Text] [Related]
16. Liposomal amphotericin B: a review of its use as empirical therapy in febrile neutropenia and in the treatment of invasive fungal infections.
Moen MD; Lyseng-Williamson KA; Scott LJ
Drugs; 2009; 69(3):361-92. PubMed ID: 19275278
[TBL] [Abstract][Full Text] [Related]
17. Budget impact analysis of liposomal amphotericin B and amphotericin B lipid complex in the treatment of invasive fungal infections in the United States.
Yang H; Chaudhari P; Zhou ZY; Wu EQ; Patel C; Horn DL
Appl Health Econ Health Policy; 2014 Feb; 12(1):85-93. PubMed ID: 24385260
[TBL] [Abstract][Full Text] [Related]
18. Pharmacoeconomic analysis of amphotericin B lipid complex versus liposomal amphotericin B in the treatment of fungal infections.
Kuti JL; Kotapati S; Williams P; Capitano B; Nightingale CH; Nicolau DP
Pharmacoeconomics; 2004; 22(5):301-10. PubMed ID: 15061680
[TBL] [Abstract][Full Text] [Related]
19. An open study of the comparative efficacy and safety of caspofungin and liposomal amphotericin B in treating invasive fungal infections or febrile neutropenia in patients with haematological malignancy.
Ellis M; Frampton C; Joseph J; Alizadeh H; Kristensen J; Hauggaard A; Shammas F
J Med Microbiol; 2006 Oct; 55(Pt 10):1357-1365. PubMed ID: 17005784
[TBL] [Abstract][Full Text] [Related]
20. Attributable hospital cost and antifungal treatment of invasive fungal diseases in high-risk hematology patients: an economic modeling approach.
Ananda-Rajah MR; Cheng A; Morrissey CO; Spelman T; Dooley M; Neville AM; Slavin M
Antimicrob Agents Chemother; 2011 May; 55(5):1953-60. PubMed ID: 21357302
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
